J Cancer 2011; 2:329-330. doi:10.7150/jca.2.329

Short Report

A Clinical Study of a Cell-Based MAGE-A3 Active Immunotherapy in Advanced Melanoma Patients

Vincenzo Russo1, Francesca Lunghi2, Raffaella Fontana1, Marco Bregni3 ✉

1. Cancer Gene Therapy Unit, San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, Italy;
2. Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, Italy;
3. Strategic Program in Oncology, San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, Italy.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Citation:
Russo V, Lunghi F, Fontana R, Bregni M. A Clinical Study of a Cell-Based MAGE-A3 Active Immunotherapy in Advanced Melanoma Patients. J Cancer 2011; 2:329-330. doi:10.7150/jca.2.329. Available from http://www.jcancer.org/v02p0329.htm

File import instruction

Abstract

In this bi-institutional study, twenty-three stage IIIC-IV MAGE-A3+ melanoma patients were vaccinated with M3TK-GML biweekly at three dose levels, with a subsequent phase of vaccinations at the maximum dose level. Anti-MAGE-A3 and anti-TK T cells were assessed by in vitro assay and delayed-type hypersensitivity skin testing.

Keywords: MAGE-A3, Melanoma, Immunotherapy